IL128801A - Pharmaceutical composition comprising a substance inhibiting no synthase - Google Patents

Pharmaceutical composition comprising a substance inhibiting no synthase

Info

Publication number
IL128801A
IL128801A IL12880197A IL12880197A IL128801A IL 128801 A IL128801 A IL 128801A IL 12880197 A IL12880197 A IL 12880197A IL 12880197 A IL12880197 A IL 12880197A IL 128801 A IL128801 A IL 128801A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
synthase
substance
substance inhibiting
syntase
Prior art date
Application number
IL12880197A
Other languages
English (en)
Other versions
IL128801A0 (en
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of IL128801A0 publication Critical patent/IL128801A0/xx
Publication of IL128801A publication Critical patent/IL128801A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12880197A 1996-09-06 1997-09-05 Pharmaceutical composition comprising a substance inhibiting no synthase IL128801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9610875A FR2753098B1 (fr) 1996-09-06 1996-09-06 Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
PCT/FR1997/001567 WO1998009653A1 (fr) 1996-09-06 1997-09-05 Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene

Publications (2)

Publication Number Publication Date
IL128801A0 IL128801A0 (en) 2000-01-31
IL128801A true IL128801A (en) 2005-05-17

Family

ID=9495505

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12880197A IL128801A (en) 1996-09-06 1997-09-05 Pharmaceutical composition comprising a substance inhibiting no synthase

Country Status (14)

Country Link
US (1) US6297281B1 (de)
EP (1) EP0939654B1 (de)
JP (1) JP2000517336A (de)
AT (1) ATE264692T1 (de)
AU (1) AU734296B2 (de)
CA (1) CA2264901C (de)
DE (1) DE69728782T2 (de)
ES (1) ES2221066T3 (de)
FR (1) FR2753098B1 (de)
IL (1) IL128801A (de)
NO (1) NO991100L (de)
NZ (1) NZ334597A (de)
RU (1) RU2174844C2 (de)
WO (1) WO1998009653A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017998A1 (en) * 1997-05-16 2003-01-23 Snow Alan D. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP1068868A3 (de) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistischer Zusammensetzung, der Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeneration
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
EP1096950B1 (de) * 1998-07-10 2003-09-10 Duke University Anwendung der hemoproteine in der therapie
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
GB9827393D0 (en) * 1998-12-11 1999-02-03 Univ London Treatment of erectile dysfunction in diabetes patients
FR2787447B1 (fr) * 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
EP1013272A1 (de) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Beeinflussung der Aktivität eines Stickoxidradikalherstellungsweges zur Behandlung von mit freien Sauerstoffradikalen verbundenen Krankheiten
US6075045A (en) * 1999-04-28 2000-06-13 Ajinomoto Co., Inc. Method of treating paralysis of the extremities caused by cerebral infarction
DE19962267A1 (de) * 1999-12-23 2001-06-28 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren NO-Synthasehemmern und einer oder mehreren Ascorbylverbindungen zur Stärkung der Barrierefunktion der Haut
EP1808169B8 (de) * 1999-12-30 2012-07-04 Proteotech Inc. Polyhydroxylierte aromatische Verbindungen zur Behandlung von Amyloidose und $g(a)-Synuklein-Fibrillen-Erkrankungen
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
DE10000840A1 (de) * 2000-01-12 2001-07-19 Beiersdorf Ag Verwendung eines oder mehrerer NO-Synthasehemmer
IL152792A0 (en) * 2000-06-08 2003-06-24 Univ Texas Heterocycle derivatives and methods of use
AU2001268422A1 (en) * 2000-06-15 2001-12-24 University Of Kentucky Research Foundation Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
DK1315505T3 (da) * 2000-09-05 2008-03-03 Meditor Pharmaceuticals Ltd Farmaceutiske præparater mod hovedpine, migræne, kvalme og emesis
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
CH694549A5 (de) 2001-01-16 2005-03-31 Dr Matthias Rath Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
DE10111054A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
DE10111049A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10111052A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10219644A1 (de) * 2002-05-02 2003-11-20 Johannes Wohlrab Verwendung vom Agmatin zur topischen Applikation
SI1511710T1 (sl) 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
GB0214147D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Formulations
EP1790648A1 (de) * 2002-10-11 2007-05-30 Proteotech, Inc. Verwendung von Procyanidin B2 und dessen Verwendung zur Herstellung eines Medikaments zur Behandlung von amyloid- und synucleinbasierten Krankheiten
US20050234026A1 (en) * 2003-11-10 2005-10-20 Weinberg Joe B Method and agent for inducing apoptosis/cell death in leukemia cells
US20090186929A1 (en) * 2003-11-10 2009-07-23 U.S. Department Of Veterans Affairs Method and agent for inducing apoptosis/cell death in leukemia cells
RU2361862C2 (ru) 2003-12-29 2009-07-20 Сепракор Инк. Пиррольные и пиразольные ингибиторы daao
WO2006002082A2 (en) * 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US8283327B2 (en) 2005-03-19 2012-10-09 Kneller Bruce W Palatinose for enhancing dietary supplement and pharmaceutical delivery
PT2471530T (pt) 2005-06-01 2017-04-19 Edison Pharmaceuticals Inc Produtos terapêuticos com atividade redox para o tratamento de doenças mitocondriais e de outras condições e modulação de biomarcadores energéticos
WO2007004523A1 (ja) * 2005-07-04 2007-01-11 Tokyo Medical And Dental University Ｌ－アルギニン含有医薬組成物及び飲食品用組成物
EP1986636B1 (de) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol- und 1,4-benzochinon-derivate zur verwendung in der behandlung von erkrankungen der mitochondrien
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2273273A1 (de) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer
SI2470168T1 (en) * 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
JP6411215B2 (ja) * 2011-11-22 2018-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CN119054693B (zh) * 2024-07-17 2025-09-12 中国农业科学院麻类研究所 一种芥子酸植物生长调节剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320484D0 (en) * 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
EP0729356A1 (de) * 1993-11-17 1996-09-04 Duke University Medical Center Verwendung von stickstoffoxid-synthase-inhibitoren zur behandlung von autoimmunerkrankungen
DE69425287T2 (de) * 1994-11-15 2001-03-15 Moreno Paolini N-hydroxypiperidine als superoxid-radikalfänger

Also Published As

Publication number Publication date
NO991100L (no) 1999-05-05
IL128801A0 (en) 2000-01-31
AU734296B2 (en) 2001-06-07
ATE264692T1 (de) 2004-05-15
NO991100D0 (no) 1999-03-05
DE69728782D1 (de) 2004-05-27
AU4211197A (en) 1998-03-26
JP2000517336A (ja) 2000-12-26
CA2264901A1 (fr) 1998-03-12
EP0939654B1 (de) 2004-04-21
FR2753098A1 (fr) 1998-03-13
DE69728782T2 (de) 2005-04-28
CA2264901C (fr) 2006-01-03
WO1998009653A1 (fr) 1998-03-12
ES2221066T3 (es) 2004-12-16
RU2174844C2 (ru) 2001-10-20
NZ334597A (en) 2000-10-27
FR2753098B1 (fr) 1998-11-27
US6297281B1 (en) 2001-10-02
EP0939654A1 (de) 1999-09-08

Similar Documents

Publication Publication Date Title
IL128801A (en) Pharmaceutical composition comprising a substance inhibiting no synthase
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
ZA985364B (en) Pharmaceutical formulations containing voriconazole.
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
HUP0200522A3 (en) Triazole compounds with dopamine-d3-receptor affinity, pharmaceutical compositions containing them and their use
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
CA2326485A1 (en) Anticancer compositions
IL145475A0 (en) Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same
EP1374908A3 (de) Polymere-Arzneimittel Konjugate die eine Hydrazidolinkergruppe enthalten
IL158355A0 (en) CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0000167A3 (en) Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them
GB2367004B (en) A cyclosporin containing composition in the form of a capsule
HUP9900346A3 (en) Endoparasiticidal pharmaceutical compositions containing avermectines and depsipeptides
HU9600427D0 (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
BG103714A (en) Pararacetamol-containing tablet
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
EP0960885A4 (de) Depsipeptide und medikamente, welche dieselben als aktive ingredienzien enthalten
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
ZA971746B (en) Taxoids, their preparation and pharmaceutical compositions containing them.
HUP0000249A3 (en) Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositons containing them
EP0967222A4 (de) Zyklische depsipeptide und arzneistoffe, die diese als aktiven bestandteil beinhalten

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees